Our comprehensive guide hospitals information helps you quickly locate a hospital anywhere in the world. Our database contains in excess of 16,000 hospitals, making it one of the best places to find information on the hospital you are searching for. To assist you with locating a hospital, you can refine your search by selecting the country in which the hospital is located and choose to search by either hospital name, city/town or state/county.

 Home>> Stelara (ustekinumab)

Stelara (ustekinumab)

General Information

Stelara (ustekinumab) is a human IgG1k monoclonal antibody that binds with high affinity and specificity to the p40 protein subunit used by both the interleukin (IL)-12 and IL-23 cytokines. IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation.

Stelara is specifically indicated for the the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Stelara is supplied as a solution for subcutaneous injection. The recommended initial dose of the drug is as follows:
For patients weighing ≤100 kg (220 lbs): 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks.
For patients weighing >100 kg (220 lbs): 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks. The 45 mg dose was also shown to be efficacious in this population. However, 90 mg resulted in greater efficacy in these subjects.


Additional Information

For additional information regarding Stelara or plaque psoriasis, please visit the Stelara web page.


Clinical Results

FDA Approval
The FDA approval of Stelara was based on two multicenter, randomized, double-blind, placebo-controlled studies: STUDY 1 (n=766) and STUDY 2 (n=1,230). All subjects were 18 years of age and older with plaque psoriasis over a minimum body surface area of 10%, and Psoriasis Area and Severity Index (PASI) score >12, and who were candidates for phototherapy or systemic therapy. In both studies, subjects were randomized to the following groups: placebo at Weeks 0 and 4 followed by crossover to Stelara (either 45 mg or 90 mg) at Weeks 12 and 16; or Stelara 45 mg or 90 mg doses, regardless of weight, at Weeks 0, 4, and 16. In both studies, the endpoints were the proportion of subjects who achieved at least a 75% reduction in PASI score (PASI 75) from baseline to Week 12 and treatment success (cleared or minimal) on the Physician???s Global Assessment (PGA). In STUDY 1, the PASI75 response was reached by 3%, 67% and 66% of the placebo and Stelara 45 mg and 90 mg doses, respectively. The PGA of Cleared or Minimal was reached by 4%, 59% and 61% of the placebo, Stelara 45 mg and 90 mg doses, respectively. Subjects in STUDY 1 were evaluated through Week 52. At Week 40, those who were PASI 75 responders at both Weeks 28 and 40 were re-randomized to either continued dosing of Stelara at Week 40 or to withdrawal of therapy (placebo at Week 40). At Week 52, 89% of subjects re-randomized to Stelara treatment were PASI 75 responders compared with 63% of subjects re-randomized to placebo (treatment withdrawal after Week 28 dose). In STUDY 2, the PASI75 response was reached by 4%, 67% and 76% of the placebo and Stelara 45 mg and 90 mg doses, respectively. The PGA of Cleared or Minimal was reached by 4%, 68% and 73% of the placebo, Stelara 45 mg and 90 mg doses, respectively. In subjects who weighed <100 kg, response rates were similar with both the 45 mg and 90 mg doses; however, in subjects who weighed >100 kg, higher response rates were seen with 90 mg dosing compared with 45 mg dosing.


Mechanism of Action

Stelara (ustekinumab) is a human IgG1k monoclonal antibody that binds with high affinity and specificity to the p40 protein subunit used by both the interleukin (IL)-12 and IL-23 cytokines. IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation. In in vitro models, ustekinumab was shown to disrupt IL-12 and IL-23 mediated signaling and cytokine cascades by disrupting the interaction of these cytokines with a shared cell-surface receptor chain, IL-12 ??1.


Literature References

Side effects

Adverse events associated with the use of Stelara may include, but are not limited to, the following:

  • Nasopharyngitis
  • Upper respiratory tract infection
  • Headache
  • Fatigue
  • Diarrhea

Treatment

plaque psoriasis

Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Alimta (pemetrexed for injection) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Atracurium Besylate Injection Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Aredia (pamidronate disodium for injection) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Alrex Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Provenge (sipuleucel-T) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Cetrotide Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Ranexa (ranolazine) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Panretin Gel Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Zenapax Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Rectiv (nitroglycerin) ointment 0.4% Tekamlo (aliskiren + amlodipine) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Raplon Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Cialis (tadalafil) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Livalo (pitavastatin) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Pramipexole Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Arthrotec Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Qutenza (capsaicin) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Prestalia (perindopril arginine and amlodipine besylate) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Belviq (lorcaserin hydrochloride) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Abthrax (raxibacumab) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Activella (Estradiol/Norethindrone Acetate) Tablets Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Reminyl (galantamine hydrobromide) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print RespiGam (Respiratory Syncitial Virus Immune Globulin Intravenous) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Opdivo (nivolumab) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Pulmozyme (dornase alfa) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Atridox Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Cyramza (ramucirumab) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Altabax (retapamulin) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Propecia Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Perjeta (pertuzumab) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Aptivus (tipranavir) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Proscar Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Rilutek (riluzole) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Remeron (Mirtazapine) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Fycompa (perampanel) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Anoro Ellipta (umeclidinium and vilanterol inhalation powder) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Claritin-D 24 Hour Extended Release Tablets (10 mg loratadine, 240 mg pseudoephedrine sulfate) Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Acular (ketorolac tromethamine ophthalmic solution) 0.5% Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print PhosLo Select an option ICD-9 and ICD-10 ICD-9CM ICD-10CM Back News | Share | Print Plegridy (peginterferon beta-1a)